Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Evan Y Yu

Showing results (181-190 of 234) with videos related to

Pageof 24
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 15, 2024
Trastuzumab Deruxtecan with Nivolumab in HER2-Expressing Metastatic Breast or Urothelial Cancer: Analysis of the Phase Ib DS8201-A-U105 StudyErika Hamilton, Matthew D Galsky, Sebastian Ochsenreither, et al.
Urologic Oncology|February 8, 2021
Patterns and timing of perioperative blood transfusion and association with outcomes after radical cystectomyLeonidas N Diamantopoulos, Rishi R Sekar, Sarah K Holt, et al.
Clinical Genitourinary Cancer|May 7, 2023
Sarcomatoid Urothelial Carcinoma Is Associated With Limited Response to Neoadjuvant Chemotherapy and Poor Oncologic Outcomes After Radical CystectomyRishi R Sekar, Leonidas N Diamantopoulos, Dimitra R Bakaloudi, et al.
Urologic Oncology|May 2, 2025
Prospective evaluation of comprehensive geriatric assessments in multidisciplinary bladder cancer care and implications for personalized vulnerability phenotypingDana Cavanaugh, Sarah K Holt, Erin Dwyer, et al.
European Urology|August 5, 2025
Neoadjuvant Pembrolizumab and Accelerated Methotrexate, Vinblastine, Doxorubicin, and Cisplatin in Nonurothelial Histologic Subtypes of Muscle-invasive Bladder Cancer: A Phase 2 TrialRuben Raychaudhuri, Ali Raza Khaki, Mary W Redman, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 30, 2024
Association of Tumor Mutational Burden and PD-L1 with the Efficacy of Pembrolizumab with or without Chemotherapy versus Chemotherapy in Advanced Urothelial CarcinomaAude Fléchon, Rafael Morales-Barrera, Thomas Powles, et al.
BJU International|November 5, 2020
Neoadjuvant chemotherapy plus radical cystectomy versus radical cystectomy alone in clinical T2 bladder cancer without hydronephrosisFrancesco Soria, Peter C Black, Adrian S Fairey, et al.
Urologic Oncology|September 3, 2025
Agreement between transurethral resection of bladder tumor and radical cystectomy pathology in patients with bladder cancer subtype histology: A retrospective cohort studyDimitra Rafailia Bakaloudi, Elizabeth L Koehne, Jenna M Voutsinas, et al.
Research Square|January 10, 2024
ASSESSMENT OF CELL SURFACE TARGETS IN METASTATIC PROSTATE CANCER: EXPRESSION LANDSCAPE AND MOLECULAR CORRELATESAzra Ajkunic, Erolcan Sayar, Martine P Roudier, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 26, 2023
Tucatinib and Trastuzumab for Previously Treated Human Epidermal Growth Factor Receptor 2-Positive Metastatic Biliary Tract Cancer (SGNTUC-019): A Phase II Basket StudyYoshiaki Nakamura, Nobumasa Mizuno, Yu Sunakawa, et al.
Pageof 24

Showing results (181-190 of 234) with videos related to

Sort By:
Pageof 24
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 15, 2024
Trastuzumab Deruxtecan with Nivolumab in HER2-Expressing Metastatic Breast or Urothelial Cancer: Analysis of the Phase Ib DS8201-A-U105 StudyErika Hamilton, Matthew D Galsky, Sebastian Ochsenreither, et al.
Urologic Oncology|February 8, 2021
Patterns and timing of perioperative blood transfusion and association with outcomes after radical cystectomyLeonidas N Diamantopoulos, Rishi R Sekar, Sarah K Holt, et al.
Clinical Genitourinary Cancer|May 7, 2023
Sarcomatoid Urothelial Carcinoma Is Associated With Limited Response to Neoadjuvant Chemotherapy and Poor Oncologic Outcomes After Radical CystectomyRishi R Sekar, Leonidas N Diamantopoulos, Dimitra R Bakaloudi, et al.
Urologic Oncology|May 2, 2025
Prospective evaluation of comprehensive geriatric assessments in multidisciplinary bladder cancer care and implications for personalized vulnerability phenotypingDana Cavanaugh, Sarah K Holt, Erin Dwyer, et al.
European Urology|August 5, 2025
Neoadjuvant Pembrolizumab and Accelerated Methotrexate, Vinblastine, Doxorubicin, and Cisplatin in Nonurothelial Histologic Subtypes of Muscle-invasive Bladder Cancer: A Phase 2 TrialRuben Raychaudhuri, Ali Raza Khaki, Mary W Redman, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 30, 2024
Association of Tumor Mutational Burden and PD-L1 with the Efficacy of Pembrolizumab with or without Chemotherapy versus Chemotherapy in Advanced Urothelial CarcinomaAude Fléchon, Rafael Morales-Barrera, Thomas Powles, et al.
BJU International|November 5, 2020
Neoadjuvant chemotherapy plus radical cystectomy versus radical cystectomy alone in clinical T2 bladder cancer without hydronephrosisFrancesco Soria, Peter C Black, Adrian S Fairey, et al.
Urologic Oncology|September 3, 2025
Agreement between transurethral resection of bladder tumor and radical cystectomy pathology in patients with bladder cancer subtype histology: A retrospective cohort studyDimitra Rafailia Bakaloudi, Elizabeth L Koehne, Jenna M Voutsinas, et al.
Research Square|January 10, 2024
ASSESSMENT OF CELL SURFACE TARGETS IN METASTATIC PROSTATE CANCER: EXPRESSION LANDSCAPE AND MOLECULAR CORRELATESAzra Ajkunic, Erolcan Sayar, Martine P Roudier, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 26, 2023
Tucatinib and Trastuzumab for Previously Treated Human Epidermal Growth Factor Receptor 2-Positive Metastatic Biliary Tract Cancer (SGNTUC-019): A Phase II Basket StudyYoshiaki Nakamura, Nobumasa Mizuno, Yu Sunakawa, et al.
Pageof 24